Results 101 to 110 of about 4,861,637 (146)

Continuation of Tarlatamab With Concomitant Radiotherapy for Oligoprogression in Extensive-Stage Small-Cell Lung Cancer: A Report of Two Cases. [PDF]

Cureus
Masui R, Omori S, Ueno T, Komiya K.
europepmc   +1 more source

Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician's choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II). [PDF]

BMJ Open
Connolly E, White M, Siva S, Bressel M, See A, Hunter K, Tan J, Panettieri V, Day D, Byrne K, McCartney A, Webber K, Woodford K, David S.   +13 more
europepmc   +1 more source

First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. [PDF]

J Cancer, 2019
Xu Q, Liu H, Meng S, Jiang T, Li X, Liang S, Ren S, Zhou C.   +7 more
europepmc   +1 more source

Continuation of First-Line Systemic Therapy with Progression-Directed Radiotherapy in Patients with Oligoprogressive Hepatocellular Carcinoma: A Multicenter, Single-Arm, Phase II Trial. [PDF]

Clin Cancer Res
Shi F, Wang H, Yang Y, Ding L, Ding Y, Zhang Y, Xi M, Qu Y, Chen Z, Lu Y, Yang Y, Liu L, Yue J.   +12 more
europepmc   +1 more source

Beyond safety: rethinking concomitant radiotherapy and trastuzumab deruxtecan in metastatic breast cancer - from feasibility to precision practice. [PDF]

Breast
Tan Y, Cheng B, He K, Xie X.
europepmc   +1 more source

The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial. [PDF]

Clin Transl Radiat Oncol
Ruicci KM, Helou J, Barry A, Ye XY, Koch CA, Croke J, Han K, Rodin D, Hahn E, Kwan JYY, Yan M, Liu FF, Lindsay P, Javor J, Bedard P, Cescon D, Kumar V, Amir E, Nadler MB, Lee R, Glicksman RM.   +20 more
europepmc   +1 more source

Treatment of oligometastatic lung cancers: new data, new drivers, new approaches. [PDF]

BMJ Oncol
O'Dwyer N, Palma DA.
europepmc   +1 more source

Continuation of first-line therapy with progression-directed local therapy: a potential 1.5-line strategy bridging the gap between first- and second-line systemic therapy in oligoprogressive hepatocellular carcinoma. [PDF]

Hepatobiliary Surg Nutr
Zhang X, Yue J, Zhao L.
europepmc   +1 more source

Case Report: Exceptional long-term survival in metastatic pancreatic ductal adenocarcinoma after repeated high-dose hypofractionated lesion-directed radiotherapy. [PDF]

Front Oncol
Ding M, Song Z, Di Y, Wang Y, Ren G.
europepmc   +1 more source

Hong Kong Urological Association-Hong Kong Society of Uro-Oncology 2025 consensus on the management of locally advanced or metastatic renal cell carcinoma. [PDF]

Front Oncol
Poon DMC, Kwong PWK, Chan SYS, Ho BSH, Lam MHC, Law KS, Leung AKC, Leung CLH, Leung DKW, Ma WK, Wo BBW, Wong KCW, Wu PY, Chiu PKF.   +13 more
europepmc   +1 more source